Total Economic Impact Study Reveals Ivanti Neurons for Unified Endpoint Management Solutions Delivered 261% ROI
Accel-funded finbots.ai makes three new senior leadership hires to accelerate revenue growth in the region
LFST Shareholder Update: Robbins LLP Reminds Investors of Class Action Against LifeStance Health Group, Inc. (LFST)
2ND STREET TAIWAN CO., LTD. to Open a Twelfth Store in Taiwan, for the First Location in Kaohsiung, in Southern Taiwan. 2nd STREET Kaohsiung Dream Mal
Anaergia Reports Second Quarter 2022 Financial Results and Files Restated Financial Statements and MD&A
Xianyang High-Tech Industrial Development Zone Dedicates Ten Years to Build Up Modern New City Featured with Industry-City Integration
Australian tech entrepreneur Jennifer Zanich joins remote workforce platform Cloudstaff
TUYA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Against Tuya Inc. and Announces Opportunity for Investors with Substantial
Tokens.com Reports Operating and Financial Results for Q2 2022
Farmers Edge Announces Filing of Articles of Continuance and Appointment of CEO to the Company's Board of Directors
-
XREX is ISO/IEC 27001 Certified, Validating Its Crypto Security Credentials
TAIPEI, Aug. 16, 2022 /PRNewswire/ -- Blockchain neo fintech company XREX announced today that it has successfully acquired ISO/IEC 27001 accreditation issued by the International Organization for Standardization (ISO), confirming its ability to achieve world-class standards in maintaining its information security management system (ISMS). Crypto-fiat exchange XREX successfully acquired ISO/IEC 27001 accreditation Certified by the British Standards Institution (BSI), XREX now joins leading cryptocurrency exchanges and platforms such as Binance, Crypto.com, and Cybavo, to adhere to ISO/IEC 27001's strict requirements for ISMS. XREX achieved the certification with zero faults across all 114 criteria in its application process. "The ability to prevent and mitigate cyber risks efficiently is crucial not just to crypto firms, but all companies in this day and age," said XREX co-founder and CEO Wayne Huang. "As crypto and blockchain technologies develop, platforms that are able to uphold these principles will be those trusted by banks, regulators, users, and the masses. I am proud that XREX ranks amongst the best of these platforms." ISO certification has not been a requirement for crypto service providers under any jurisdiction, yet proactively going through such a rigorous audit proves XREX's resolve to be not just a compliant platform, but one that pursues the highest standards in cybersecurity and data protection. "Leveraging decades of collective experience in cybersecurity, the XREX security team has built precise defense mechanisms and threat-monitoring models. We proactively applied for the ISO/IEC 27001:2013 certification and passed BSI's audit," said Sun Huang, Chief Security Officer and General Manager at XREX who led the entire ISO application program. "XREX will continue to strive for the highest international standards, joining the global movement in building a safer environment for blockchain and crypto adoption." XREX acquired official approval in May 2022 to be a crypto asset service provider in Lithuania and Money Services Business (MSB) licenses from both the United States Financial Crimes Enforcement Network (FinCEN) and Canada. It is in the process of applying to the Monetary Authority of Singapore (MAS) for a Major Payment Institution license, which will allow XREX to conduct digital payment token services. About XREX XREX is a neo fintech leveling the playing field by partnering with banks, regulators, and verified individuals to redefine banking together. Our blockchain-driven solutions create a collective financial system that empowers all to participate and contribute to the global economy. Founded in 2018 and headquartered in Taipei, XREX comprises a team of world-leading experts in cybersecurity, fintech, compliance, and cryptocurrency to offer a full suite of innovative products such as BitCheck, XREX Earn, XREX Clubs, and Risk Level Detector to solve dollar-liquidity shortage issues faced by cross-border merchants in emerging economies. Follow XREX on Discord, Telegram, Twitter, Facebook, and LinkedIn.
-
Nintendo News: Wave Race 64 Brings Surf, Sand and Speed to Nintendo Switch Online + Expansion Pack on Aug. 19
REDMOND, Wash.--(BUSINESS WIRE)--#nintendoswitch--Jump on your watercraft and feel the rumble of the waves, because another classic game is about to make a splash in the growing Nintendo 64™ library on the Nintendo Switch™ system! Starting Aug. 19, the Wave Race™64 game will be available for everyone with a Nintendo Switch Online + Expansion Pack membership. Available soon as part of the Nintendo 64 – Nintendo Switch Online collection, Wave Race 64 is a fast and fluid racing game originally released shortly after the launch of the Nintendo 64 system in 1996. Choose from one of four watercraft racers, each with their own abilities and style, and try to capture glory in Championship Mode, whip around the tracks in Time Trials, pull off tricks in Stunt Mode or challenge a friend in 2P VS. Mode.* Wave Race 64 features nine challenging courses set across scenic locales. Go airborne with dolphins on the golden shores of Sunset Bay, cruise under the bright lights and tall buildings of Twilight City, feel the crashing waves on Sunny Beach or chill out on the frigid waters of Glacier Coast, just to name a few. Plus, racing conditions will change with the weather, making the water choppy or covering the course with fog. The waves will even respond to the way that you and your rivals move! The wet and wild Wave Race 64 game is just one of the many sports and racing games now available on Nintendo Switch, including fellow Nintendo 64 games Mario Kart™ 64, F-Zero™ X, Mario Golf™, and Mario Tennis™, as well as Nintendo Switch games such as the Mario Golf sequel Mario Golf™: Super Rush, Nintendo Switch™ Sports and Mario Strikers™: Battle League, among many others. The Nintendo Switch Online + Expansion Pack membership plan features all the same great benefits of a Nintendo Switch Online membership, but with access to a library of classic Nintendo 64 and SEGA Genesis games with added online play. A paid Nintendo Switch Online + Expansion Pack membership also grants access to the Animal Crossing™: New Horizons - Happy Home Paradise, Mario Kart™ 8 Deluxe – Booster Course Pass and Splatoon™ 2: Octo Expansion DLC** at no extra cost. Members in both Nintendo Switch Online plans can enjoy online play and the Save Data Cloud feature in a large selection of compatible games, along with access to over 100 classic NES™ and Super NES™ games, a smartphone app that enhances features of supported games, and the competitive online battle game PAC-MAN™ 99. Both plans also provide a great way to connect and play compatible games online with friends and family around the world. With online play in compatible games like Mario Golf™: Super Rush, Animal Crossing™: New Horizons, Pokémon™ Legends: Arceus, Splatoon™ 2, Super Smash Bros.™ Ultimate, Mario Kart 8 Deluxe and many others, a Nintendo Switch Online membership can help you experience everything Nintendo Switch has to offer. For more information about all the benefits and services available with the Nintendo Switch Online and Nintendo Switch Online + Expansion Pack memberships, and to learn about a free seven-day Nintendo Switch Online trial, go to the Nintendo Switch Online section on the Nintendo Switch HOME Menu or visit https://www.nintendo.com/switch/online-service/. Nintendo Switch Online or Nintendo Switch Online + Expansion Pack membership (sold separately) and Nintendo Account required for online features. Nintendo Switch Online + Expansion Pack membership required to access Nintendo 64 – Nintendo Switch Online and SEGA Genesis – Nintendo Switch Online libraries of games. Free Nintendo Switch Online trial automatically converts to 1-month auto-renewing membership unless automatic renewal is turned off by the end of the free trial. Credit card/PayPal account required for 18+. Free trial cannot be redeemed for a Nintendo Switch Online + Expansion Pack membership nor by a Nintendo Account with an active Individual Membership or Family Membership. Persistent Internet, compatible smartphone and Nintendo Account age 13+ required to access some online features on the app, including voice chat. Data charges may apply. Online features, Save Data Cloud and Nintendo Switch Online smartphone app features available in compatible games. Not available in all countries. The Nintendo Account User Agreement, including the Purchase and Subscription terms, apply.nintendo.com/switch-online * Additional accessories may be required for multiplayer mode. Sold separately. ** Full version of game required to use DLC for that game. Sold separately. Animal Crossing: New Horizons © 2020 Nintendo F-Zero X © 1998 Nintendo Mario Golf © 1999 Nintendo/CAMELOT Mario Golf: Super Rush © Nintendo/CAMELOT Mario Kart 64 © 1996 Nintendo Mario Kart 8 Deluxe © 2017 Nintendo Mario Strikers: Battle League © Nintendo Mario Tennis © 2000 Nintendo/CAMELOT PAC-MAN 99 ©BANDAI NAMCO Entertainment Inc. Published by BANDAI NAMCO Entertainment America Inc. Pokémon Legends: Arceus © 2022 Pokémon. © 1995-2022 Nintendo/Creatures Inc./GAME FREAK inc. Splatoon 2 © 2017 Nintendo Super Smash Bros. Ultimate © 2018 Nintendo Original Game: © Nintendo / HAL Laboratory, Inc. Wave Race © 1996 Nintendo. Kawasaki's trademarks used with the permission of Kawasaki Heavy Industries, Ltd. Note to editors: Nintendo press materials are available at https://press.nintendo.com, a password-protected site. To obtain a login, please register on the site. Contacts Nelia-Sol White Golin 213-335-5508 nwhite@golin.com Justin Aclin Golin 212-373-6004 jaclin@golin.com
-
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Maligna
ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors and hematologic malignancies. SHANGHAI and HONG KONG, Aug. 16, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the first patient has been dosed in the Phase I ATRIUM trial to evaluate ATG-018 as a monotherapy in patients with advanced solid tumors and hematologic malignancies in Australia. The ATRIUM trial is a Phase I multi-center, open-label, dose finding study of ATG-018 monotherapy in patients with advanced solid tumors or hematologic malignancies. The primary objective of the study is to evaluate the safety and tolerability of ATG-018 and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) and/or biologically effective dose of ATG-018 monotherapy and preliminary efficacy, if available. The secondary objective is to characterize the pharmacology of ATG-018. ATG-018 is an orally-available, potent, selective small molecule ATR inhibitor. ATG-018 inhibits the ATR kinase, which limits cancer cells' ability to repair damaged DNA, in a mechanism also known as synthetic lethality or the DDR. "In human cells, a variety of repair mechanisms exist to maintain genomic integrity, and defects in these pathways cause genome instability and promote tumorigenesis. Many cancer cells have high level replication stress and rely on their S/G2 checkpoints for survival following DNA damage. This renders tumor cells more susceptible to inhibition of ATR and targeting this may be a novel therapeutic strategy," said Dr Jim Coward, Chair of Icon's Medical Oncology Research Committee and Associate Professor at University of Queensland School of Medicine. "ATG-018, is an oral, potent, and selective inhibitor of ATR. Preclinical studies have demonstrated potent activity against ATR in enzyme inhibition assays and tumor cell lines including both solid tumors and hematological malignancies. We are encouraged by these findings, and eager to further evaluate the therapeutic potential of ATG-018 for patients." Dr. Jay Mei, Antengene's Founder, Chairman and CEO said, "ATG-018 is a novel in-house discovered and developed drug candidate to enter the clinical stage. I am very proud of the joint efforts from the teams at Antengene and the clinical organizations to bring this compound to the clinical stage. Data on ATG-018 presented at 2022 American Association for Cancer Research (AACR 2022) Annual Meeting showed that ATG-018 has demonstrated promising single-agent activity in a robust preclinical program that includes a wide range of tumor types that rely on DDR and have a need for new treatments. In addition, early work to identify a set of predictive biomarkers could enable ATG-018 to be used as a precision-medicine. We will work closely with our investigators to advance this clinical program and strive to develop a new treatment option for patients around the world." About ATG-018 Developed by the internal R&D Team at Antengene, ATG-018 is an oral, potent, selective small molecule inhibitor targeting ataxia telangiectasia and Rad3-associated (ATR) kinase. ATR kinase belongs to the phosphoinositide 3 kinase-related family. Inhibiting ATR kinase leads to increased accumulation of single-strand DNA breaks, particularly meaningful for tumor cells which rely on DNA damage repair (DDR). Preclinical studies have demonstrated that ATR inhibitor monotherapy or combination with other drugs (including DDR agents) could be promising therapeutic strategies for solid tumors (including gastric, esophageal, squamous cell carcinoma) and hematologic malignancies (chronic lymphocytic leukemia [CLL], diffuse large B-cell lymphoma [DLBCL] and multiple myeloma [MM]). According to a preclinical poster presented at 2022 American Association for Cancer Research (AACR 2022) Annual Meeting, ATG-018 has demonstrated potent in vitro and in vivo monotherapy efficacy in solid tumor/hematologic cancer models with certain homologous recombination deficiencies. These data were supported by a series of genetic alterations that correlated with ATG-018 sensitivity and could be potential predictive biomarkers. Taken together, these data suggest that ATG-018 could be a promising therapeutic agent for patients with such homologous recombination deficiencies/genetic alterations. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has a built broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this press release relate only to the events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this press release completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this press release, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this press release. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.comMobile: +86 13062747000
-
TEST EW 2022 AUG 15 TEST
Lorem IpsumSAN SAN--(BUSINESS WIRE)--$buds #allworkandnoplay--Ipsum morbi nec augue faucibus dui ad pellentesque posuere nulla litora senectus nostra duis ridiculus odio vulputate porttitor porta litora fringilla porta sem. Sit erat arcu semper quis. Rhoncus tortor dictumst nascetur condimentum lectus placerat potenti vehicula pede luctus lobortis interdum. Praesent nonummy per mattis dictumst vestibulum, phasellus, tellus sem conubia, dictum nisi purus massa. Laoreet tincidunt convallis id curabitur Molestie nullam vestibulum enim. Dolor tristique fringilla varius semper primis lorem dui nullam. Cum ac nisi hendrerit lacus nam porta placerat turpis lobortis felis maecenas sodales Sollicitudin euismod mattis cum facilisi ante quisque pretium facilisis tincidunt convallis hac. Suscipit sagittis ipsum sociis eleifend proin ad libero morbi sit inceptos in egestas. Magnis urna suspendisse feugiat diam dictumst cum accumsan volutpat convallis euismod euismod id mattis primis penatibus senectus magnis mollis sed rhoncus at. Nullam molestie nostra nibh platea magnis lobortis curae; aliquam Lacinia malesuada nunc Morbi habitasse. Tempus per felis pede nulla rutrum per dui. Ad nulla diam lectus dui lobortis egestas suspendisse, ultrices condimentum curae; commodo montes mus sodales habitasse fringilla, malesuada bibendum mi nec blandit velit commodo hac sed magnis lorem, sodales, dui massa. Taciti facilisi Gravida. In parturient, platea tempor duis tempor natoque pretium urna. Phasellus sollicitudin orci montes inceptos a pretium donec Per luctus tincidunt semper proin duis egestas. Nunc primis mollis nascetur dictumst senectus nonummy. Faucibus lectus. Massa, venenatis primis justo Auctor euismod enim tellus donec iaculis class elit congue class nonummy fames bibendum netus ullamcorper amet turpis habitant ornare imperdiet proin malesuada adipiscing lobortis risus et placerat semper mattis vulputate aenean ante. Posuere semper leo vestibulum. Pellentesque molestie velit ut elit. Viverra nascetur metus volutpat ullamcorper Commodo per. Platea nam. Nisl Blandit eget litora. Sagittis, sociosqu Taciti at metus pharetra turpis risus. Sapien. Proin elementum. Est nascetur, adipiscing mus phasellus. Litora faucibus fringilla, lacinia, mollis inceptos nonummy massa eros adipiscing. Morbi vivamus hac. Posuere lacinia mus cubilia curabitur placerat metus. Erat morbi a curabitur consequat. Lobortis enim. Dictumst auctor a fames nec placerat porttitor pretium. Orci lorem donec lobortis et purus hendrerit. Non donec augue parturient praesent neque imperdiet. Amet. Dolor gravida cum elementum. Sociis. Magnis. Congue Lacinia. Eget lobortis id hendrerit cursus venenatis luctus pharetra id. Urna convallis et, faucibus porta pulvinar tempor torquent vivamus mus. Sem curabitur mus nec imperdiet hendrerit mauris turpis amet ridiculus porta tincidunt sed pharetra nisi, pretium a neque inceptos aenean erat nisi dis porta cursus. Magna maecenas semper. Magnis. https://www.test.businesswire.com/news/home/20220421000476/en Elit nulla dictum volutpat phasellus facilisi quam luctus sem montes aptent iaculis auctor ac, placerat purus litora commodo molestie posuere phasellus. Hendrerit eleifend. Purus neque pharetra. Iaculis lacus pede mollis natoque. Rutrum penatibus risus, fermentum malesuada tempus consectetuer magnis placerat libero dictumst nascetur augue ullamcorper dis. Risus amet porttitor lorem ultricies sociosqu quisque convallis tempor ridiculus inceptos volutpat blandit lacus ipsum. Sociosqu dictum tincidunt quis bibendum semper, odio. Tellus lacus ante. Euismod. Erat sociis rhoncus habitant semper. Nibh posuere vitae rhoncus donec tempus fames. Tempor ante adipiscing taciti laoreet lacinia est. Class. Nulla, fusce est ultricies posuere litora. Condimentum placerat tempus litora arcu Posuere quis. Per duis enim elit class hac Rutrum fusce pharetra. Dapibus, ridiculus proin fermentum libero lacinia. Pede, amet hac, facilisis nisl consequat sollicitudin venenatis tortor tempor etiam. Phasellus quis massa faucibus sed non odio maecenas quis justo egestas habitant sagittis donec. Feugiat viverra adipiscing integer montes vel pede. Luctus urna pulvinar montes. Penatibus ut libero ornare nibh pulvinar ultricies tempus. Torquent. Diam porttitor praesent potenti in laoreet potenti litora cubilia consequat vehicula convallis ultrices tempus lorem molestie vitae metus velit auctor turpis ornare, senectus commodo ipsum suspendisse lectus quis torquent quis, purus commodo facilisi. Contacts test@test.test
-
Jining hosts carbon materials industry summit
JINING, China, Aug. 16, 2022 /PRNewswire/ -- A news release from GLOBAL TIMES ONLINE: The China (Jining) Advanced Carbon Materials Industry Development Summit Forum was held in Jining's Jiaxiang county in East China's Shandong province on Aug 7. More than 100 representatives from the domestic carbon materials industrial chain, including top-notch experts Liu Zhongfan and Xu Chunming, attended the forum to discuss in-depth cooperation initiatives between governments, industries, universities and research institutes and how to boost high-quality development within the industry. Jiaxiang county is currently home to more than 20 production and sales enterprises and covers carbon-based materials, high-end carbon application materials, new-energy graphite products, asphalt new materials and lithium cell materials. In 2021, the sector's output value exceeded 4 billion yuan ($592.4 million). The county has established partnerships with more than 20 universities and research institutes including Tsinghua University and China University of Petroleum to form a close-loop industrial chain consisting of research and development, production, and application. Shandong Yida New Material Co based in Jiaxiang is one of the major domestic suppliers of petroleum-based needle coke. In 2021, the company produced 200,000 tons of petroleum-based needle coke, ranking first in China, and exported 13,000 tons of petroleum-based needle coke, which accounted for over 50 percent of the country's total exports of the product.
-
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 16, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announced it has received notice from the U.S. Food and Drug Administration (FDA) that it may proceed with a Phase 2 clinical study of BBT-877, an autotaxin inhibitor to treat patients with idiopathic pulmonary fibrosis (IPF). (US IND Number: IND 140199, NCT identifier: NCT05483907). Following a Type C meeting for proceeding development of BBT-877 with the FDA in June 2021, the company submitted non-clinical data inclusive of in vivo comet assays with transmission electron microscopy (TEM) evaluation, and the protocol to fully support the safety of clinical studies in IPF patient participants. The U.S. FDA finally approved the final protocol, and confirmed the advancement of Phase 2 clinical study of BBT-877. "We're excited to continue the clinical development of BBT-877 in order to address unmet medical needs of IPF," said James Lee, founder and CEO of Bridge Biotherapeutics. "With this approval, the company remains focused on developing novel treatment options for multiple fibrotic diseases, including IPF." Bridge plans to initiate the 24-week Phase 2 clinical study later this year. The multi-country study will include approximately 50 clinical sites in North America, Asia, and Europe. Further information is available at www.clinicaltrials.gov/show/NCT05483907. STUDY TITLE: A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as mono- or add-on therapy, in Patients with Idiopathic Pulmonary Fibrosis (IPF) STUDY DESIGN: Placebo-controlled and double-blind in North America, Asia, and Europe TEST PRODUCT: BBT-877 100 mg capsules, or placebo capsules, 2 capsules taken orally twice a day for six months PRIMARY OUTCOME MEASURES: Change from baseline in FVC (in mL) compared to placebo at Week 24 stratified by presence/absence of add-on therapy About Bridge Biotherapeutics, Inc. Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. About Autotaxin Autotaxin (ATX), a protein of approximately 900 amino acids discovered in the early 1990s, is an important enzyme for generating the lipid-signaling molecule, lysophosphatidic acid (LPA). Autotaxin's lysophospholipase D activity converts lysophosphatidylcholine (LPC) into LPA, which engages in signaling via LPA receptors. LPA signaling results in cell proliferation, migration, secretion of cytokines and chemokines, and reduction of cell apoptosis. Ultimately, autotaxin has a pathogenic role in processes of inflammation and fibrosis, making it an attractive drug target. BBT-877, an experimental autotaxin inhibitor, demonstrated LPA inhibition of up to 90 percent in multiple-ascending dose cohorts of the Phase 1 study. About idiopathic pulmonary fibrosis (IPF) IPF is a rare, debilitating and fatal lung disease which affects approximately 3 million people worldwide. Progression of IPF is variable and unpredictable, and over time the lung function of an IPF patient gradually and irreversibly declines.
-
GLOBAL SENSATION FLEURS DE VILLES FEMMES MAKES ITS AUSTRALIA DEBUT AT THE ROYAL BOTANIC GARDEN SYDNEY - THE FLORAL EVENT OF THE YEAR
From August 19 - 28 2022, experience Fleurs de Villes FEMMES, a 10-day public event of fresh floral couture by local florists at the Royal Botanic Garden Sydney in The Calyx, in celebration of remarkable women SYDNEY, Aug. 16, 2022 /PRNewswire/ -- World-renowned bespoke floral show, Fleurs de Villes, is thrilled to announce the launch of its very first public showing in Sydney, the major events capital of the Asia Pacific, in partnership with the Royal Botanic Garden Sydney and the NSW Government, through its tourism and major events agency Destination NSW. From August 19 - 28 at The Calyx, the FEMMES exhibition will bring people together to celebrate remarkable women and spread joy through the beauty of fresh floral works of art. FEMMES will showcase a series of fresh floral mannequins created by local floral talent, each based on a photograph or painting of 17 inspirational women. Visitors to FEMMES will be able to learn more about these fascinating subjects by scanning QR codes on the floral sculptures that will link to their incredible stories. Participating florists include Persephone, Blue Flowers, Don De L'Amour, Flowerun Flower Studio, Butchers Daughter, Sydney Events Stylist, My Floral Designer, Art of Bloom, Beks Bloomz, Buds & Bowers, Florada, Hayfever Flowers, Max & Co Floral Design, Moss & Bloom, SLAK Flowers, Styled with Ellie, Flowers by Julia G, Claire Howard Bryan and Petal Bang. Fleurs de Villes is delighted to be able to offer Sydney's floral artists a platform of creativity within the Royal Botanic Garden to showcase their talent on a global platform. L-R: Frida Kahlo, Oprah Winfrey and Audrey Hepburn floral tributes featured at previous Fleurs de Villes FEMMES city exhibitions. Photo Credit: Fleurs de Villes Fleurs de Villes FEMMES will feature these 17 remarkable women of cultural significance and historical impact: Malala Yousafzai - A Pakistani activist for female education and human rights, Yousafzai is also the youngest person in the world to receive the Nobel Peace Prize. Frida Kahlo - Possibly the most well-known female painter of modern times, Kahlo is famous for her ground-breaking self-portraits and works inspired by the nature and artefacts of her native Mexico. Kylie Minogue - Pop superstar Kylie Minogue is the highest-selling female Australian artist of all time, having sold over 80 million records worldwide. Ash Barty - Three-time Grand Slam singles champion, Ash Barty was the second Australian tennis player to be ranked No. 1 in the world, holding the ranking for 121 weeks. Dr. Evelyn Scott - Trailblazing social activist and educator, Dr. Evelyn Scott spent her life tirelessly campaigning for the rights of Aboriginal and Torres Strait Islander peoples, and was instrumental to many of the key achievements in Australia's reconciliation journey to date. Dame Nellie Melba - Australia's first international star, "Queen of Song" Nellie Melba sang in all the major opera houses in Europe and USA for almost 40 years. Jenny Kee - A pioneer of Australian style and internationally acclaimed artist and designer since the 1970s, Jenny Kee is best known for her vibrant art and designs that reflect her passion for the unique and precious Australian environment. Olivia Newton-John - Affectionately dubbed "Olivia Neutron-Bomb" for her high-energy performances, Olivia Newton-John was a singer, dancer, activist and actress, adored by fans around the globe. Nancy Bird Walton - Pioneering Australian aviator Nancy Bird Walton founded the Australian Women Pilots' Association and earned the nickname 'The Angel of the Outback' for her flying medical service. Miles Franklin - Best known for her novel My Brilliant Career, Australian writer and feminist Miles Franklin is renowned for her outright rejection of traditional women's roles in her novels. Carla Zampatti - Iconic Australian fashion designer Carla Zampatti crafted timeless, effortless and essential womenswear for more than 55 years. Edith Cowan - Australia's first female parliamentarian, social reformer Edith Cowan spent her life advocating for the rights and welfare of women and children. Margaret Flockton - Australia's first female lithographer Margaret Flocton was the most accomplished botanical artist in New South Wales in her day. Her art has since been rediscovered and exhibited at the Royal Botanic Garden Sydney. Ada Lovelace - Pioneer of computing science, Ada Lovelace's fascination with the male-dominated fields of science and mathematics led to her farsighted insight into the potential of computers. Nicole Kidman - Emmy, Golden Globe and Academy Award winning actress Nicole Kidman is best known for her varied film and TV roles, including that of Satine in Baz Luhrmann's Moulin Rouge, and her work as a UNIFEM Goodwill Ambassador. Greek Goddess Demeter - One of the most widely celebrated Olympians, Demeter was the Greek goddess who reigned over crops, harvests, family, and fertility. Dr. Barbara Briggs - One of Australia's leading botanists, Barbara Briggs has described and reclassified 80 species and performed ground-breaking research into botanical evolutionary relationships during her 59 years at the Royal Botanic Garden Sydney. As well as those featured at The Calyx at Royal Botanic Garden Sydney, floral tributes to three more inspirational women will be exhibited around Sydney. FEMMES will celebrate Greek Goddess Persephone at the Four Seasons Hotel Sydney, and Delta Goodrem and Miranda Kerr at Myer, Sydney. Fleurs de Villes is beautifully supported by local partners Genesis Motors Australia, Four Seasons Hotel Sydney, Moulin Rouge! The Musical, Myer, Australian Women's Weekly and smoothfm. Part of the proceeds from ticket sales go to the Foundation and Friends of the Botanic Gardens, a not-for-profit organisation that is devoted to supporting, protecting and enhancing the Royal Botanic Garden Sydney and their vital scientific research and conservation projects. Sydney has a combination of natural wonders and cultural experiences like nowhere else in the world, and visitors to FEMMES can experience both with the botanical event program taking place at Sydney's beautiful Botanic Garden throughout the 10 day show. Highlights include a "flower-bombed" car sponsored by Genesis, a pop-up flower market on Sunday 24th August, a "JARDIN" area hosting floral demonstrations, workshops and talks from florists, scientists and horticulturists, and bespoke dining experiences including a French High Tea and Bottomless Rosé Brunch. Visitors are encouraged to vote for their favourite mannequin for a chance to win an urban staycation in the at Four Seasons Hotel Sydney, including crafted cocktails in Grain Bar. They can also enter a "snap and share" social media contest for a chance to win 4 tickets to Moulin Rouge! The Musical by snapping a photo of their favourite installation, tagging #FDVFEMMES and following @fleursdevilles. Tickets can be purchased at botanicgardens.org.au/femmes General admission to The Calyx is $22, and $11 for seniors and children 5-17 years. General Information Digital press kit with high-resolution images and video - access HEREEvent Dates: August 19th 2022 to August 28th 2022Admission Fee: $22 for adults, $11 for children and seniorsWebsite: www.rbgsyd.nsw.gov.au/femmesFleurs de Villes social media: Instagram, Facebook, TikTok The Royal Botanic Garden Sydney social media: Instagram, Facebook, Twitter ABOUT FLEURS DE VILLES Founded in 2015 by lifestyle and media experts Tina Barkley and Karen Marshall, Fleurs de Villes is a Vancouver-based luxury brand specializing in bespoke fresh-floral experiences and activations. Champion of experiential marketing in the form of large-scale floral installations, Fleurs de Villes brings brands and shopping districts to life through fresh-floral place-making, retail engagement, and collaborations with some of the world's biggest luxury brands and entertainment franchises. To date, Fleurs de Villes has produced 54 floral events in 23 cities in 4 countries (Canada, United States, UK and Australia), celebrating the talent of over 700 florists. Leveraging local floral talent in every city, Fleurs de Villes creates authentic, engaging, 360 degree experiences with omni-channel touch points across digital, video, social, print, and In-Real-Life platforms. ABOUT THE ROYAL BOTANIC GARDEN SYDNEY The Royal Botanic Garden Sydney is Australia's oldest living scientific institution and is home to an outstanding collection of more than 27,000 plants from around the world. The Garden is also a part of the Australian Institute of Botanical Science. The Institute consists of the physical and virtual scientific collections, research, services, and facilities, and of course, staff at the Royal Botanic Garden Sydney, Australian Botanic Garden Mount Annan, and the Blue Mountains Botanic Garden Mount Tomah. The Institute is one of the nation's premier botanical research organisations and helps to ensure the survival of plants and build more resilient ecosystems for future generations. #FleursDeVillesFEMMES #FlowersMakeUsHappy
-
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more evidence to support upcoming Phase III clinical trials in China, the U.S. and the European Union SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has completed the first subject dosing in the U.S. drug-drug interaction (DDI) study of Farnesoid X receptor (FXR) agonist ASC42 for treatment of primary biliary cholangitis (PBC). This DDI study is expected to enroll 12 subjects in total in August 2022 and be completed by the beginning of the fourth quarter 2022 in the U.S. The DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more evidence to support upcoming Phase III clinical trials in China, the U.S. and the European Union for treatment of PBC. PBC is a chronic autoimmune cholestatic disease and frequently progresses to liver fibrosis and cirrhosis requiring liver transplantation or resulting in death. In response to the increasing incidence, Asian Pacific Association for the Study of the Liver (APASL) developed the clinical practice guidance on the diagnosis and management of patients with PBC in 2022. PBC is gaining extensive attention as both the incidence and prevalence has showed an increasing tendency globally [1]. An epidemiology study indicates that there were approximately 120,000 PBC patients in the U.S. in 2014[2]. Ursodeoxycholic acid (UDCA) is the standard treatment for PBC, however, approximately 40% PBC patients have an inadequate response to or are unable to tolerate UDCA[3]. For those patients with insufficient UDCA response or intolerance, Obeticholic Acid (OCA) is the only approved medicine in the U.S. while it has not been approved in China yet. Additionally, OCA may significantly cause pruritus and low density lipoprotein cholesterol (LDL-C) levels to rise. ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential and global intellectual property. Previous Phase I clinical trial in the U.S. (ClinicalTrials.gov Identifier: NCT04679129) demonstrated that ASC42 might be a potentially best-in-class PBC drug candidate as LDL-C levels were in normal range with no pruritus occurrence, and FXR target engagement biomarker FGF19 increased 1,780% when ASC42 was dosed at 15 mg, once daily (QD) during the 14-day treatment. Currently, FXR agonist ASC42 is in Phase II clinical trial in China. The Phase II study (ClinicalTrials.gov Identifier: NCT05190523) consists of three ASC42 active treatment arms (5 mg, 10 mg and 15 mg) and one placebo control arm at the ratio of 1:1:1:1 and is expected to enroll a total of 100 patients who have an inadequate response to or are unable to tolerate UDCA. The treatment duration is 12 weeks. Gannex intends to initiate Phase III clinical trials in China, the U.S. and the European Union after the completion of the ongoing Phase II clinical trial in China. "It only took us two months to complete the first subject dosing after the application of DDI study was approved by the U.S. FDA. This fast progress, once again, demonstrated the execution excellence of our team. Gannex is advancing clinical trials of FXR agonist ASC42 in both China and the U.S. to meet the unmet medical needs for patients with PBC. We are dedicated to improving the current treatments of PBC and providing more options for patients." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. [1] Lv T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;36:1423–1434.[2] Lu M, Zhou Y, Haller I V, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment [J]. Clin Gastroenterol Hepatol 2018, 16(8): 1342-50 e1. DOI: 10.1016/j.cgh.2017.12.033.[3] Lindor K D, Bowlus C L, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases [J]. Hepatology 2019, 69(1): 394-419. DOI: 10.1002/hep.30145. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 20 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit www.ascletis.com.
-
Enochian Biosciences Inc. Shareholder Notice: Robbins LLP is Investigating Enochian Biosciences Inc. (ENOB) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)--$ENOB #ENOB--Shareholder rights law firm Robbins LLP is investigating Enochian Biosciences Inc. (NASDAQ: ENOB) and its officers and directors to evaluate whether they violated securities laws or breached fiduciary duties by overstating the Company's commercial prospects for its product pipeline. Enochian is a pre-clinical stage biotechnology company that purportedly researches and develops pharmaceutical and biological products for the human treatment of human immunodeficiency virus, hepatitis B virus, influenza and coronavirus infections, and cancer. If you would like more information about our investigation of Enochian Biosciences Inc.'s misconduct, click here. What is this Case About: According to a class action complaint filed against Enochian, Enochian and its top management have credited Dr. Serhat Gumrukcu, Enochian's co-founder and largest shareholder, as a "genius" and the "inventor" of the technology and science behind the Company's product pipeline. However, defendants failed to disclose to shareholders that Gumrukcu had no verifiable degrees beyond high school and therefore, the scientific and technological underpinnings of Enochian's product pipeline purportedly invented by Gumrukcu were dubious at best. As such, defendants significantly overstated the commercial prospects for the Company's product pipeline. Further, Gumrukcu had a criminal history, including fraud, of which Enochian's senior leadership was aware. On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy. On this news, the price of Enochian's stock fell almost 37%, to close at $3.70 per share on May 25, 2022. Then, on June 1, 2022, Hindenburg Research published a report on Enochian highlighting the murder-for-hire plot, as well as the other crimes committed by Gumrukcu. Specifically, Gumrukcu "was arrested based on accusations of falsely posing as a doctor" in Turkey in 2012, and "[i]n February 2017, Gumrukcu was arrested by authorities after the State of California accused him of a slew of white-collar crimes, including fraud, identify theft, and check kiting – a total of 14 felonies." On this news, Enochian's stock fell another 28.42%, to close at $3.765 per share on June 1, 2022. Next Steps: If you acquired shares of Enochian Biosciences Inc. between September 24, 2020 and May 31, 2022, you have legal rights. Contact Robbins LLP for more information about your legal options. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas (800) 350-6003 adumas@robbinsllp.comShareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Enochian Biosciences Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contacts Aaron Dumas Robbins LLP 5040 Shoreham Place San Diego, CA 92122 adumas@robbinsllp.com(800) 350-6003 www.robbinsllp.com
-
Weber Inc. Shareholder Notice: Robbins LLP is Investigating Weber Inc. (WEBR) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)--$WEBR #IPO--Shareholder rights law firm Robbins LLP is investigating Weber Inc. (NYSE: WEBR) and its officers and directors to determine whether they violated securities laws or breached fiduciary duties in connection with statements made in anticipation of the Company's August 2021 initial public offering ("IPO"). Weber is an outdoor cooking company that sells grilling products across the world. If you would like more information about our investigation of Weber Inc.'s misconduct, click here. What is this Case About: According to the class action complaint filed against the Company and certain of its officers and directors, defendants held the Company's IPO on August 6, 2021, selling almost 18 million shares at $14.00 per share. However, the Registration Statement in support of the IPO was materially false and failed to state that Weber was reasonably likely to implement price increases, which would result in decreased demand for their products. The resulting inventory buildup would then result in Weber running promotions to "enhance retail sell through," which would adversely impact Weber's financial results. On July 25, 2022, Weber announced its preliminary third quarter 2022 financial results, including net sales between $525 million and $530 million. The Company expected to report a net loss, noting that “[p]rofitability was negatively impacted by” several factors, including “promotional activity to enhance retail sell through.” Additionally, Weber announced that Chris Scherzinger “is departing” from his roles as Chief Executive Officer and director of the Company. On this news, the Company’s stock price fell $1.21 per share, or 16%, to close at $6.30 per share on July 25, 2022. By the commencement of the class action, the Company’s stock was trading as low as $6.25 per share, a nearly 55% decline from the $14 per share IPO price. Next Steps: If you acquired shares of Weber Inc. pursuant to the Company's IPO, you have legal options. Please contact Robbins LLP for more information about your rights and remedies. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas (800) 350-6003 adumas@robbinsllp.comShareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Weber Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contacts Aaron Dumas Robbins LLP 5040 Shoreham Place San Diego, CA 92122 adumas@robbinsllp.com(800) 350-6003 www.robbinsllp.com
-
Korean Skincare Brand Dear, Klairs Expands Japanese Offline Distribution Channels by Launching in Four Largest Stores
Additional launching after entering 125 offline stores of PLAZA and MINiPLA in Japan in May Packaged design in Japanese is applied to Dear, Klairs’ three steady seller products, presenting customized packages for local customers A “SKINCARE TRIAL KIT” gift event will be held on the official Klairs Japan Instagram account until August 31 in celebration of its launch SEOUL, South Korea--(BUSINESS WIRE)--#CosmeStore--Dear, Klairs, the representative skincare brand of Wishcompany (CEO Soungho Park), a Korean beauty brand, content, and commerce company, announced its expansion to the four largest offline distribution channels in Japan. The four offline distribution channels are a beauty select shop "shop in," an urban home center "Tokyu Hands," Japan's representative lifestyle store "PLAZA," and a household goods chain "Loft." In addition, it will launch the product in Japan's most prominent beauty specialty shop, "@Cosme Store" (listed in katakana order). The products to be released in Japan are Dear, Klairs' steady sellers, such as Supple Preparation Facial Toner (180ml), Freshly Juiced Vitamin Drop (35ml), Freshly Juiced Vitamin E Mask (90ml), and more. The brand also plans to introduce to the Japanese market some of its products that are gaining popularity in Korea and overseas. "New package designs for Japanese customers will be available in the newly launched stores,” said Lee Seungeun, Head of Wishcompany's Japan Sales Team. “We plan to strengthen contact points with the customers through localized packages and promotions.” Dear, Klairs is holding an event to celebrate its launch on Dear, Klairs’ official Japanese Instagram account until August 31st. Customers can participate by posting pictures of the purchased products with a hashtag and following the brand’s official Instagram account (www.instagram.com/klairs.jp). A total of 60 winners will be selected and gifted with a SKINCARE TRIAL KIT containing four travel-sized personal care items worth 2,700 JPY. Dear, Klairs, a skincare brand that proposes a balanced life, started in Seoul, Korea, in 2010. It has focused on products that people will use to the end and repurchase, rather than selling various products that pursue trends. The brand has established itself as a representative K-beauty line by introducing its products to 64 countries and rising to the top of the sales rankings in major global distribution channels. For more information, visit https://www.wishcompany.net/ Contacts WISHCOMPANY PR Team Berry Jeon Rosa Kim +82 70-4366-5365 comm_lab@wishcompany.net
-
upGrad Completes Investment Round of USD 210 Million
MUMBAI, India--(BUSINESS WIRE)--#ACC--upGrad, Asia's higher edtech major, has announced a fresh round of fundraise from marquee investors and Family Offices who join the company cap-table. This round has witnessed participation from ETS (world’s largest TOEFL & GRE Test Leader), Bodhi Tree (a JV of James Murdoch & Uday Shankar), Singapore's Kaizen Management Advisors Pvt. Ltd, Family office of Bharti Airtel, Narotam Sekhsaria Family Office (Ambuja Cements and ACC), and Artian Investments along with existing investors Temasek, IFC and IIFL. Founder Group also invested USD 12.5 million in this round to maintain their over 50% ownership in upGrad. “We welcome our new investors and industry veterans to the upGrad cap table. There is a massive Re-skilling Revolution taking place around the world and over the last 5 years our 4800+ colleagues have worked hard & smart to be at the epicenter of taking advantage of this, not just in India but around the world. Higher EdTech will be on the rise for the next 4 to 5 decades. upGrad in the last 12 months has re-shaped itself to be the most integrated company in this space with career opportunities for the College learners and Working Professionals from the age of 18 to 58 and will be a LifeLongLearning partner for millions in the coming years. We have always been very capital efficient while growing 100% year-on-year and hope to retain that discipline,” said upGrad Co-founders, Ronnie Screwvala and Mayank Kumar in a joint statement while commenting on the fund raise. “upGrad is a leader in digital reskilling and upskilling in India, and rapidly becoming a worldwide leader in this burgeoning education area,” said ETS Strategic Capital Managing Director Ralph Taylor-Smith. “We are excited to invest in, and partner with, upGrad to help accelerate its growth. India continues to be a priority country for ETS, and we are dedicated to strategically increasing our footprint in this key market. Our partnership with upGrad will help to advance our shared mission of providing educational opportunities for all learners, in the South Asia region and around the globe.” upGrad team strength will grow to 7600 from the present 4800 in the next 3 months and will also include about 170 full-time faculty, 1600 teachers, and over 5000 on-contract coaches and mentors, thereby building one of the largest full-time Edtech faculty in the world. Bucking the slowdown trend within the sector, upGrad has remained bullish with its program completion rate of 80%+ and has emerged as a global leader in the higher education segment. 40% of the company's total revenue is realised from Repeats and Referrals year-on-year. About upGrad upGrad - started in 2015 is a pioneer in the online education revolution, focused on powering career success for a global workforce of over 1.3 billion. It is one of the few Integrated LifeLongLearning Tech Companies in the world - spanning the college learner to the working professional from the age group of 18-50 years and across Undergrad courses, Campus & Job Linked Programs, Studying Abroad, short form to executive programs to Degrees, Masters and Doctoral - with a learner base of over 3 million across 100+ countries and over 300 University partners and a robust enterprise business with a client base of 1000 companies worldwide. upGrad’s Global Learning Engine rests on four pillars - (a) its large repository of original & owned content and IP, (b) its own best-in-class proprietary tech platform, (c) it's high touch human-led delivery service backed by coaches & mentors, and (d) an 85% course completion track record, backed by a further 80% career outcomes guaranteed performance. Already termed Asia’s higher EdTech leader it has offices in the UK, U.S., Middle East, India, Singapore & Vietnam, and with a presence in many more countries Contacts upGrad | Neha Prasad | neha.prasad@upgrad.com
-
Triton Digital Releases the Australian Podcast Ranker for July 2022
SYDNEY--(BUSINESS WIRE)--Triton Digital®, the global technology and services leader to the digital audio and podcast industry, announced today the release of the latest Australian Podcast Ranker. The Ranker provides insight into the Top 100 Podcasts as well as the Top 100 Australian-Made Podcasts and the Top 10 Publishers in Australia from 1 July through 31 July, 2022, as measured by Triton’s Podcast Metrics measurement service. This month, Triton Digital introduced a Sales Representation Ranker in Australia in addition to the standard monthly Podcast Ranker. The Sales Representation Ranker lists the top entities providing advertising sales representation to the podcasts and publishers participating in the Australian Podcast Ranker. The sales representation rankings are based on the volume of monthly listeners and these results can be found on australianpodcastranker.com. Results are de-duplicated for sales representation that represents multiple publishers. The Top Podcast Ranker and Australian-Made Top 100 Ranker are ranked by monthly listeners, in accordance with the latest IAB Podcast Technical Measurement Guidelines. Yet again, for this reporting period, the top three publishers were ARN’s iHeartPodcast Network Australia, LiSTNR (SCA), and Audioboom. There were several debuts on the Top 100 Ranker from The Execution of Bonny Lee Bakley (Wondery), Who Killed Daphne? (Wondery), Good Weekend Talks (Nine Publishing), and more. For the Australian-Made Top 100 Ranker, there were also several debuts including, Flex & Froomes (ARN/iHeartPodcast Network Australia), SBS Cycling Podcast (Special Broadcasting Services), Dear Clementine (NOVA Entertainment), and more. Participating publishers in the Australian Ranker include Audioboom, ARN’s iHeartPodcast Network Australia, DM Podcasts, Equity Mates Media, Hidden Brain Media, LiSTNR (SCA), Motorsport Podcast Network, News Corp Australia, Nine, NOVA Entertainment, Podshape, Schwartz Media, Special Broadcasting Service, Sports Entertainment Network (SEN), Stitcher Media, Studio71, TOFOP Productions, The Chaser, Wavelength Creative, and West Australian Newspapers. To view the full list of Top 150 and the Top 15 Publishers from this month, please visit Triton Digital’s online Australian Podcast Ranker. Or, if you would like to receive future rankers via email, please subscribe. Triton Digital’s Podcast Metrics measurement service is certified by the IAB Tech Lab as complying with Version 2.1 of the IAB Podcast Measurement Technical Guidelines. It provides accurate and insightful data around how, when, and where podcast content is being consumed across multiple hosting platforms, with the ability to view metrics by date range, location, device, podcast name, episode, title, and more. About Triton Digital Triton Digital® is the global technology and services leader to the digital audio and podcast industry. Operating in more than 80 countries, Triton provides innovative technology that enables broadcasters, podcasters, and online music services to build their audience, maximize their revenue, and streamline their day-to-day operations. In addition, Triton powers the global online audio industry with Webcast Metrics®, the leading online audio measurement service and Podcast Metrics, one of the first IAB certified podcast measurement services in the industry. With unparalleled integrity, excellence, teamwork, and accountability, Triton remains committed to connecting audio, audience, and advertisers to continuously fuel the growth of the global online industry. For more information, visit www.TritonDigital.com. Contacts For More Information, Press Only: Sarah Graham fama PR for Triton Digital Tritondigital@famapr.com Judy Shaw Commercial Radio Australia +61 (0)418 415 965 Judy.Shaw@commercialradio.com.au
-
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-in-class and best-in-class drug candidates, and expand product portfolio through strategic transactions and internal drug discovery efforts SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has entered into an agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), whereby Immunomedics will obtain exclusive rights to develop and commercialize Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the "Agreement"). Under the terms of the Agreement, Everest will receive up to $455 million in total considerations with $280 million in upfront payments payable subject to, among other things, certain regulatory approvals, and up to $175 million in potential future milestone payments. In addition, Everest will be released from payment obligations for up to $710 million in remaining milestone payments under a licensing agreement entered into with Immunomedics in April 2019 to develop, register, and commercialize Trodelvy® in Greater China, South Korea and certain other countries and territories. Under the Agreement, the licensing agreement will be terminated. Everest received approval in mainland China and Singapore in June and January 2022, respectively, for Trodelvy® in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Everest has also submitted applications for commercial approval for Trodelvy in metastatic TNBC with regulatory bodies in South Korea, Taiwan and Hong Kong. "We welcome the opportunity to restructure our partnership with Gilead, which has been built on a shared vision of providing innovative oncology solutions for patients in need. With capital resources and a track record of successful therapeutic development and commercialization for Trodelvy in the United States, Gilead is an ideal partner to further develop and commercialize Trodelvy in Asia Pacific regions to maximize patient access," said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. "I am exceedingly proud of what Everest has accomplished in advancing Trodelvy in China and other Asia territories, and we will continue to bring more transformational therapies to patients in China and worldwide with our extensive pipeline of clinical and pre-clinical stage assets." "Trodelvy is approved for second-line metastatic TNBC in over 35 countries. We thank Everest Medicines for their partnership and important contributions in the development of Trodelvy in Asia. Their collaboration has brought us closer to bringing Trodelvy to patients who need alternative options," said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences. "Trodelvy is the cornerstone of our solid tumor portfolio, and we are committed to bringing this transformative therapy to as many patients as possible. We look forward to rapidly advancing our development program in Asia and to realizing the clinical potential of Trodelvy across diverse tumor types." "After the completion of this transaction, Everest's resources will be more streamlined to invest into the ongoing development of our remaining pipeline of clinical-stage drug candidates with first-in-class or best-in-class potential. We will have a stronger balance sheet to advance our internal drug discovery efforts and execute synergistic strategic transactions," said Ian Woo, President and Chief Financial Officer of Everest Medicines. "We will strive to deliver sustained value to our shareholders and to patients in Asia and worldwide." Gilead will have the opportunity to recruit Everest employees working directly on the Trodelvy program. Goldman Sachs served as financial advisor to Everest Medicines while Ropes & Gray LLP served as legal counsel to the Company. Conference Call Information A live conference call will be hosted on August 16, 2022 at 8:30 AM Beijing Time (August 15, 2022 at 8:30 PM U.S. Eastern Time). The live webcast of the conference call will be available at https://www.acecamptech.com/eventDetail/60502830. Participants need to register in advance of the conference call. Alternatively, participants may dial in to the conference call using below dial-in information: United States: +1 646 254 3594 EnglishMainland China: +86 10 5808 4166 English +86 10 5808 4199 ChineseHong Kong: +852 3005 1313 English +852 3005 1355 ChineseUnited Kingdom: +44 20 7660 0166 EnglishInternational: +1 866 636 3243 EnglishPassword: 029169 A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://www.everestmedicines.com. About Trodelvy® (Sacituzumab Govitecan) Trodelvy is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment. Trodelvy is approved in more than 35 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Under Everest's licensing agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., Everest Medicines has exclusive rights to develop, register, and commercialize Trodelvy for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries. In October 2020, Trodelvy was included in the updated 2020 China Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer and was also included in the updated 2022 Guidelines for Breast Cancer Diagnosis and Treatment of the Chinese Society of Clinical Oncology in April. *The TRODELVY trademark is used under license from Gilead Sciences, Inc. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eleven potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company's therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
-
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
– Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. In China mainland and Singapore, Trodelvy is approved for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Gilead continues to work closely with regulatory bodies in Hong Kong, South Korea and Taiwan, where New Drug Applications, filed by Everest Medicines for metastatic TNBC, are currently under review. “Trodelvy is approved for second-line metastatic TNBC in over 35 countries. We thank Everest Medicines for their partnership and important contributions in the development of Trodelvy in Asia. Their collaboration has brought us closer to bringing Trodelvy to patients who need alternative options,” said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences. “Trodelvy is the cornerstone of our solid tumor portfolio, and we are committed to bringing this transformative therapy to as many patients as possible. We look forward to rapidly advancing our development program in Asia and to realizing the clinical potential of Trodelvy across diverse tumor types.” In April 2019, Everest Medicines and Immunomedics entered into an agreement granting Everest Medicines an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia, excluding Japan. Gilead subsequently acquired Immunomedics in October 2020 and created an extensive global clinical development program, including investigating Trodelvy as a monotherapy and in novel combinations, across multiple disease areas including non-small cell lung cancer, metastatic urothelial cancer and gastrointestinal cancers. “We welcome the opportunity to restructure our partnership with Gilead, which has been built on a shared vision of providing innovative oncology solutions for patients in need. With capital resources and a track record of successful therapeutic development and commercialization for Trodelvy in the U.S., Gilead is an ideal partner to further develop and commercialize Trodelvy in Asia Pacific regions to maximize patient access,” said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. “I am exceedingly proud of what Everest has accomplished in advancing Trodelvy in China and other Asia territories, and we will continue to bring more transformational therapies to patients in China and worldwide with our extensive pipeline of clinical and pre-clinical stage assets.” Under the terms of the agreement, Gilead will make a $280 million upfront payment to Everest. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. Gilead will also have the opportunity to recruit Everest employees working directly on the Trodelvy program. The transaction is expected to close later this year, and will be subject to customary closing conditions, including approval by Everest’s shareholders. Trodelvy U.S. Prescribing Information has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; see below for Important Safety Information. About Trodelvy Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment. Trodelvy is approved in over 35 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Trodelvy is also being developed for potential investigational use in other TNBC and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer. U.S. Indications for Trodelvy In the United States, Trodelvy is indicated for the treatment of: Adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Adult patients with locally advanced or metastatic UC who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. U.S. Important Safety Information for Trodelvy BOXED WARNING: NEUTROPENIA AND DIARRHEA Severe or life-threatening neutropenia may occur. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay. Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold Trodelvy until resolved to ≤Grade 1 and reduce subsequent doses. CONTRAINDICATIONS Severe hypersensitivity reaction to Trodelvy. WARNINGS AND PRECAUTIONS Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with Trodelvy. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever. Diarrhea: Diarrhea occurred in 65% of all patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments. Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of Trodelvy was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication is recommended. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions. Nausea and Vomiting: Nausea occurred in 66% of all patients treated with Trodelvy and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting. Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function. Embryo-Fetal Toxicity: Based on its mechanism of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Trodelvy and for 3 months after the last dose. ADVERSE REACTIONS In the ASCENT study (IMMU-132-05), the most common adverse reactions (incidence ≥25%) were fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes. In the TROPHY study (IMMU-132-06), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, neutropenia, nausea, any infection, alopecia, anemia, decreased appetite, constipation, vomiting, abdominal pain, and rash. The most frequent serious adverse reactions (SAR) (≥5%) were infection (18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes. DRUG INTERACTIONS UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy. UGT1A1 Inducers: Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy. Please see full Prescribing Information, including BOXED WARNING. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that Gilead may not realize the potential benefits of this transaction; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gilead’s ability to receive regulatory approvals for such indications in a timely manner or at all, including regulatory approvals in Hong Kong, South Korea and Taiwan for metastatic TNBC, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; the risk that physicians may not see the benefits of prescribing Trodelvy; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. U.S. Prescribing Information for Trodelvy including BOXED WARNING, is available at www.gilead.com. Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Contacts Jacquie Ross, Investors investor_relations@gilead.com Karley Ura, Media Karley.ura@gilead.com
-
Busan IT Industry Promotion Agency Selects 2022 Korea-ASEAN XR Joint Project as Bridgehead to Enter ASEAN Market
National Museum Bangkok, Thailand will exhibit its cultural heritage using Korea's XR content creation technology A selection of 9 projects amounting to about 2.3 million USD will be demonstrated and commercialized Competitive Korean XR companies are expected to enter the global market and pioneer export channels BUSAN, South Korea--(BUSINESS WIRE)--#2022KoreaASEANXRJointProject--Busan IT Industry Promotion Agency (President & CEO Mun-Seob Jeong), through the ASEAN-ROK ICT Convergence Village, announced the selection of nine new projects for the 2022 Korea-ASEAN XR Joint Project to demonstrate and to establish competitive Korean XR companies, and to expand advanced XR and Metaverse technology into the ASEAN market. Following the 2019 ASEAN-ROK Commemorative Summit held in Busan, ASEAN-ROK ICT Convergence Village was first implemented in 2020. The project with its purpose of expanding ICT exchange and mutual growth in Korea and ASEAN is under the National IT Industry Promotion Agency (NIPA) and Busan IT Industry Promotion Agency (BIPA), hosted by the Korean Ministry of Science and ICT, and Busan Metropolitan City. The nine selected projects are as follows: 1. XR museum contents and exhibition platform for National Museum Bangkok, Thailand (Fun it Co., Ltd.) 2. Indonesia virtual avatar full body motion capture live interaction project (Kovee Co., Ltd., Filder tax Co., Ltd.) 3. XR Convergence Sports Contents and Experience Center Demonstration Project in Myanmar (Insol M&T Co., Ltd., KMPI Consortium Co., Ltd.) 4. Korea and ASEAN virtual exhibition platform based on 3D immersive metaverse gallery in Myanmar (GD Communication & Asian Arts Cooperation) 5. Metaverse exercise solution customized for Vietnamese body types using body recognition technology and kiosk (Tiger AI, RH-Tech Co., Ltd., Industrial-Academic Cooperation Group of Dongmyeong University) 6. Police taser gun training system in Indonesia using VR (Jacob System Co., Ltd., Premoem Co., Ltd.) 7. Total golf training system using XR technology in Malaysia (Smile Square, Hello Studio Co., Ltd.) 8. AR-based telemedicine and collaboration system in Indonesia (Pusan National University Hospital, ITIZ, ION-M Solution Co., Ltd.) 9. XR safety education and training contents production in Brunei (Safety XR) (YST Co., Ltd.) BIPA plans to finance the aforementioned projects totaling about 2.3 million USD for its demonstration and commercialization in the ASEAN market, slated to support the application of XR content to various business fields in the ASEAN region. In 2021 alone, BIPA funded about 2.5 million USD for six projects, including the XR tourism platform construction project for the Imperial City of Hue, a UNESCO World Heritage Site, resulting in the launch of tourism products. Mun-Seob Jeong, President & CEO of BIPA, said, “I hope that the 2022 Korea-ASEAN XR Joint Project becomes a good opportunity for ASEAN and ROK to start collaborating on various projects. BIPA will continue to discover and support designated projects according to the demands of the ASEAN region.” Contacts Busan IT Industry Promotion Agency Policy Planning Department Seung-wan Han 051-749-9452 hsw1103@busanit.or.kr Digital Transformation Department Seong-il Byeon 051-715-9121 skpr12@busanit.or.kr
-
LG Chem and ADM Launch Joint Ventures, Announce Intended Location for U.S. Production of Lactic Acid and Polylactic Acid Production
Two joint ventures intend to produce 150,000 tons of lactic acid and 75,000 tons of polylactic acid annually to meet growing demand for plant-based solutions, including eco-friendly bioplastics Intended location for new production facilities will be Decatur, Illinois, U.S., with final investment decision to be made in 2023 SEOUL, South Korea & CHICAGO--(BUSINESS WIRE)--LG Chem (KRX: 051910), a leading global diversified chemical company, and ADM (NYSE: ADM), a global leader in nutrition and biosolutions, today held a signing ceremony launching two joint ventures for U.S. production of lactic acid and polylactic acid to meet growing demand for a wide variety of plant-based products, including bioplastics. Pending final investment decisions, the joint ventures have chosen Decatur, Illinois, U.S., as the location of their intended production facilities. The first joint venture, GreenWise Lactic, would produce up to 150,000 tons of high-purity corn-based lactic acid annually. ADM would be the majority owner of GreenWise, and would contribute fermentation capacity from its Decatur bioproducts facility to the venture. The second joint venture, LG Chem Illinois Biochem, would be majority-owned by LG Chem. It would build upon LG Chem’s expertise in bioplastics to build a facility that will use product from GreenWise Lactic to produce approximately 75,000 tons of polylactic acid (PLA) per year. ADM CEO Juan R. Luciano stated, “Sustainability is one of the enduring global trends that is powering ADM’s strategy and growth. Our BioSolutions platform is helping us meet that demand by redeploying Carbohydrate Solutions production capacity to fast-growing, higher-margin segments – including pharmaceuticals and personal care, textiles and paper products. BioSolutions is already growing rapidly, with $136 million in year-over-year revenue growth in the first half of 2022, and with these two new joint ventures, we’re planning to take the next growth step, greatly expanding our ability to meet growing demand for plant-based solutions. We’re pleased to expand our collaboration with LG Chem, and we’re excited at the opportunity to bring this new intended production and all of its economic benefits to Decatur, our North American headquarters.” LG Chem Chief Executive Officer Hak Cheol Shin commented, “The establishment of this joint venture is a sustainable growth strategy that can directly contribute in solving environmental issues such as climate change and waste plastics,” and added, “LG Chem is the first Korean company to build a PLA plant with integrated production capacities ranging from raw materials to the final product. With the establishment of this JV, LG Chem will not only procure production capacities for highly pure lactic acid needed for commercial-scale PLA production, but will also be able to apply biomaterials in the development of various high-value-added products. Based on eco-friendly materials, which is an axis for new growth engines, we will respond to the rapidly changing market and customers, while becoming a market leader.” Global demand for lactic acid – which is used broadly in food, feed and cosmetics in addition to industrials like bioplastics – was valued at approximately USD 2.9 billion in 2021, with an expected annual growth rate of 8%. Global demand for bioplastics and biopolymers is projected to grow from USD 10.7 billion in 2021 to USD 29.7 billion by 2026, representing annual growth of 22.7%. The joint ventures, which are subject to required regulatory approvals, hope to make final investment decisions around the Decatur projects in 2023. Pending final investment decisions and approvals, construction would be targeted to begin in 2023, and production in late 2025 or early 2026, with the two joint ventures supporting more than 125 jobs in the Decatur region. Both ventures are participating in the State of Illinois’ Economic Development for a Growing Economy (EDGE) program, which provides incentives to job creators who plan to make investments in Illinois. “I am thrilled that LG Chem and ADM have chosen Decatur as home for their joint ventures,” said Illinois Governor JB Pritzker. “Our state’s talented workforce coupled with our mission of sustainability make Illinois the best place for these lactic and polylactic acid production facilities. To LG Chem and ADM: thank you for your commitment to our state. It is innovative, plant-based solutions like these that will help us tackle the climate crisis head on.” "When I led a congressional delegation to South Korea earlier this year, I met with the CEO of LG Chem, Hak Cheol Shin, and shared how Illinois is uniquely positioned for greater investment as a growing hub for innovation, manufacturing and technology. I'm proud my advocacy helped bring this important investment to Illinois," said U.S. Senator Tammy Duckworth. “LG Chem recognizes what I’ve long known: Illinois is a great place to do business. Building on ADM's long history in Illinois, I’m glad the leaders at ADM and LG Chem made this decision to help our state lead the transition to a clean energy economy and create good-paying jobs right here so we can help build a better, more sustainable future for communities throughout Illinois. I will continue to spread the message across the country and around the world that entrepreneurs and innovative companies should call Illinois home.” “Demand for plant-based products is on the rise and it’s no surprise Illinois is attractive to companies looking to expand in this industry,” U.S. Senator Dick Durbin said. “As the federal government seeks opportunities to invest in greener buildings, it will look to states like Illinois that are leaders in the production of eco-products. Today’s news is a positive step and I appreciate the efforts of state and local leaders to bring even more jobs to Illinois.” "Decatur has a rich heritage in manufacturing products that serve as industry game-changers, and the two ADM and LG Chem ventures announced today are no exception," said Nicole Bateman, president of the Economic Development Corporation of Decatur - Macon County. "Their collective approach to plant-based innovations are a welcomed addition to the global industry leaders who call Decatur home. ADM and LG Chem will find a great partner in the EDC and City of Decatur to support their infrastructure and operational needs to bring this project to life." Forward-Looking Statements Some of the above statements constitute forward-looking statements. ADM’s filings with the SEC provide detailed information on such statements and risks and should be consulted along with this release. To the extent permitted under applicable law, ADM assumes no obligation to update any forward-looking statements. About LG Chem LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains. Headquartered in Seoul, Korea, LG Chem has multiple operation sites worldwide and generated KRW 42.7 trillion (USD 37.3 billion) in sales in 2021. For more information, please visit www.lgchem.com. About ADM ADM unlocks the power of nature to enrich the quality of life. We’re a premier global human and animal nutrition company, delivering solutions today with an eye to the future. We’re blazing new trails in health and well-being as our scientists develop groundbreaking products to support healthier living. We’re a cutting-edge innovator leading the way to a new future of plant-based consumer and industrial solutions to replace petroleum-based products. We’re an unmatched agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. And we’re a leader in sustainability, scaling across entire value chains to help decarbonize our industry and safeguard our planet. From the seed of the idea to the outcome of the solution, we give customers an edge in solving the nutritional and sustainability challenges of today and tomorrow. Learn more at www.adm.com. Source: Corporate Release Source: ADM Contacts LG Chem Contacts: Byeongmin Woo (Team Leader, Communications Team), Goh JangSeok/ (Specialist, Communications Team) (02-3773-6473, 3979) ADM Contacts: Jackie Anderson (media@adm.com; 312-634-8484)
